Tarsus Q1 2025: XDEMVY sales $78.3M, up 217% YoY; net loss narrows to $25.1M

Tarsus Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.64 revenue$78,335,000

Net product sales of XDEMVY $78.3M, up 217% vs Q1 2024 and 18% vs Q4 2024; ~72,000 bottles dispensed.
Net loss of $25.1M ($0.64 diluted loss per share), improved from $35.7M loss ($1.01 per share) in Q1 2024.
Cash, cash equivalents and marketable securities $407.9M as of March 31, 2025, bolstered by $134.8M equity offering.
SG&A expenses $85.0M, up from $51.6M, driven by DTC advertising and commercial expansion.
On track to initiate Phase 2 trial of TP-04 for Ocular Rosacea in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.